Header Logo

YAGO NIETO

TitleProfessor
InstitutionMD Anderson
DepartmentStem Cell Transplantation
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Merryman RW, Rhoades J, Xiong K, Redd RA, Antel K, An HH, McDonough M, Guerrero L, Crnjac A, Sridhar S, Blewett T, Cheng J, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Murakami M, Adalsteinsson VA. Comparison of whole-genome and immunoglobulin-based circulating tumor DNA assays in diffuse large B-cell lymphoma. Hemasphere. 2024 Apr; 8(4):e47. PMID: 38566803; PMCID: PMC10983020.
      Citations:    
    2. Valdez BC, Yuan B, Murray D, Ramdial JL, Popat U, Nieto Y, Andersson BS. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024 Mar 14; 15:220-231. PMID: 38484153; PMCID: PMC10939475.
      Citations:    Fields:    Translation:HumansCells
    3. Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin DC, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P, Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024 Mar 12; 8(5):1128-1136. PMID: 38266155; PMCID: PMC10909702.
      Citations:    Fields:    Translation:Humans
    4. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 Mar 06. PMID: 38448009.
      Citations:    Fields:    
    5. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024 Feb 14. PMID: 38355908.
      Citations:    Fields:    
    6. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 Apr; 99(4):562-569. PMID: 38314663; PMCID: PMC10947843.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784. PMID: 38238616; PMCID: PMC10957466.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    8. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4. PMID: 38199987; PMCID: PMC10781953.
      Citations:    Fields:    Translation:Humans
    9. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024 May 01; 130(9):1663-1672. PMID: 38127583; PMCID: PMC11009063.
      Citations:    Fields:    
    10. Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer. 2023 Dec 20; 23(1):1258. PMID: 38124057; PMCID: PMC10734180.
      Citations:    Fields:    Translation:Humans
    11. Nieto Y, Yang Z, Valdez BC, Kundu S, Bashir Q, Ramdial J, Srour S, Qazilbash M. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol. 2024 Feb; 99(2):245-253. PMID: 38100199.
      Citations:    Fields:    Translation:Humans
    12. Nieto Y, Banerjee P, Kaur I, Kim KH, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, Ramdial J, Srour S, Daher M, Marin D, Jiang X, Chen K, Champlin R, Shpall EJ, Rezvani K, Nieto Y, Banerjee P, Kaur I, Kim KH, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, Ramdial J, Srour S, Daher M, Marin D, Jiang X, Chen K, Champlin R, Shpall EJ, Rezvani K. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2024 Feb; 30(2):203.e1-203.e9. PMID: 38042257.
      Citations:    Fields:    Translation:HumansCells
    13. Valdez BC, Yuan B, Murray D, Ramdial JL, Nieto Y, Popat U, Tang X, Andersson BS. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol. 2023; 13:1287444. PMID: 38074694; PMCID: PMC10701888.
      Citations:    
    14. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023 Oct 24; 7(20):6196-6205. PMID: 37611156; PMCID: PMC10582839.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    15. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol. 2024 01; 204(1):e11-e16. PMID: 37822075.
      Citations:    Fields:    Translation:HumansCells
    16. Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce RM, Chen YB, Shipp MA, Herrera AF, Armand P. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759. PMID: 36399518; PMCID: PMC10468363.
      Citations:    Fields:    Translation:HumansCells
    17. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762. PMID: 37673125.
      Citations: 1     Fields:    Translation:Humans
    18. Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther. 2023 Nov; 29(11):690-694. PMID: 37607645.
      Citations:    Fields:    Translation:Humans
    19. Merrill MH, Dahi PB, Redd RA, McDonough MM, Chen YB, DeFilipp Z, Herrera AF, Fisher DC, LaCasce AS, Odejide OO, Ng SY, Jacobson CA, Merryman RW, Kim AI, Nieto YL, Sauter CS, Shah GL, Zain JM, Armand P, Jacobsen ED. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood. 2023 08 17; 142(7):621-628. PMID: 37319432; PMCID: PMC10934277.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    20. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578. PMID: 37461327; PMCID: PMC10530277.
      Citations:    Fields:    Translation:Humans
    21. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther. 2024 Feb; 30(2):205.e1-205.e12. PMID: 37437764.
      Citations: 1     Fields:    Translation:Humans
    22. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873. PMID: 37376789; PMCID: PMC10527395.
      Citations:    Fields:    Translation:Humans
    23. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757. PMID: 36827681; PMCID: PMC10275699.
      Citations: 4     Fields:    Translation:Humans
    24. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68. PMID: 37137874; PMCID: PMC10156676.
      Citations: 1     Fields:    Translation:HumansCells
    25. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Neelapu SS, Nieto Y, Strati P, Shpall EJ. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica. 2023 04 01; 108(4):1163-1167. PMID: 36384251; PMCID: PMC10071112.
      Citations: 2     Fields:    Translation:Humans
    26. Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega F. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology. 2023 Jul; 83(1):143-148. PMID: 36994939.
      Citations:    Fields:    Translation:Humans
    27. Ramdial J, Chan KH, Sanchez Petitto G, Valdez B, Andersson BS, Nieto Y. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. Bone Marrow Transplant. 2023 06; 58(6):635-638. PMID: 36966213.
      Citations:    Fields:    Translation:Humans
    28. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41. PMID: 36916461.
      Citations:    Fields:    Translation:Humans
    29. Ramdial JL, Valdez BC, Andersson BS, Nieto Y. Romidepsin antagonism with CHOEP. Leukemia. 2023 05; 37(5):1160-1161. PMID: 36906714.
      Citations:    Fields:    Translation:Humans
    30. Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq. 2023 Feb 07. PMID: 36798261; PMCID: PMC9934761.
      Citations:    
    31. Saad A, Loren A, Bola?os-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. NCCN Guidelines? Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw. 2023 02; 21(2):108-115. PMID: 36791762.
      Citations:    Fields:    Translation:Humans
    32. Pasvolsky O, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Kebriaei P, Shpall EJ, Champlin RE, Gaballa MR, Milton DR, Tang G, Lin P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6. PMID: 36646323; PMCID: PMC10040427.
      Citations: 2     Fields:    Translation:Humans
    33. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 01 01; 108(1):98-109. PMID: 35833303; PMCID: PMC9827150.
      Citations:    Fields:    
    34. Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2023 03; 29(3):189-198. PMID: 36470579; PMCID: PMC10125001.
      Citations: 1     Fields:    Translation:Humans
    35. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2022 Nov 17. PMID: 36403579.
      Citations: 2     Fields:    
    36. Roldan CJ, Huh B, Song J, Nieto Y, Osei J, Chai T, Nouri K, Koyyalagunta L, Bruera E. Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial. BMC Med. 2022 11 03; 20(1):377. PMID: 36324139; PMCID: PMC9632023.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    37. Valdez BC, Nieto Y, Yuan B, Murray D, Andersson BS. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Oncotarget. 2022 10 14; 13:1122-1135. PMID: 36243940; PMCID: PMC9564514.
      Citations: 1     Fields:    Translation:HumansCells
    38. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica. 2022 10 01; 107(10):2496-2500. PMID: 35770531; PMCID: PMC9521225.
      Citations:    Fields:    
    39. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44. PMID: 36068929; PMCID: PMC9771924.
      Citations:    
    40. Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen YB, Bonjoc KC, Chaudhry A, Herrera AF, Armand P, Merryman RW. Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2022 Dec; 63(12):2912-2917. PMID: 35938581.
      Citations:    
    41. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6. PMID: 35940528.
      Citations:    
    42. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022 10; 28(10):695.e1-695.e10. PMID: 35902049.
      Citations:    Fields:    
    43. Sheikh IN, Elgehiny A, Ragoonanan D, Mahadeo KM, Nieto Y, Khazal S. Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. Cancers (Basel). 2022 Jun 13; 14(12). PMID: 35740580; PMCID: PMC9221186.
      Citations:    
    44. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors? Transplant Cell Ther. 2022 08; 28(8):500.e1-500.e10. PMID: 35662592.
      Citations:    Fields:    
    45. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303. PMID: 35610308; PMCID: PMC9352570.
      Citations:    Fields:    
    46. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther. 2022 08; 28(8):501.e1-501.e7. PMID: 35618218.
      Citations:    Fields:    
    47. Afrough A, Alsfeld LC, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q, Milton DR. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9. PMID: 35605883.
      Citations:    Fields:    
    48. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149. PMID: 35523847.
      Citations:    Fields:    Translation:Humans
    49. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 07; 28(7):395.e1-395.e11. PMID: 35513252; PMCID: PMC10152475.
      Citations:    Fields:    Translation:Humans
    50. Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Adv. 2022 04 12; 6(7):2267-2274. PMID: 35008100; PMCID: PMC9006305.
      Citations:    Fields:    Translation:Humans
    51. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908. PMID: 33951890; PMCID: PMC8968895.
      Citations: 1     Fields:    Translation:Humans
    52. Valdez BC, Yuan B, Murray D, Nieto Y, Popat U, Andersson BS. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma. 2022 07; 63(7):1634-1644. PMID: 35188042.
      Citations:    Fields:    Translation:HumansCells
    53. Valdez BC, Murray D, Yuan B, Nieto Y, Popat U, Andersson BS. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. Oncotarget. 2022; 13:319-330. PMID: 35154579; PMCID: PMC8830224.
      Citations:    Fields:    
    54. Srour SA, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH, Milton DR. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021 12 01; 106(12):3211-3214. PMID: 34407606; PMCID: PMC8634193.
      Citations:    Fields:    Translation:Humans
    55. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721. PMID: 34686083.
      Citations: 1     Fields:    Translation:Humans
    56. Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. PMID: 34670169; PMCID: PMC8792205.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    57. Bashir Q, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N, Milton DR. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. 2022 01; 57(1):51-56. PMID: 34629467; PMCID: PMC9126091.
      Citations: 5     Fields:    Translation:HumansCells
    58. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol. 2021 12 01; 96(12):E455-E457. PMID: 34559916.
      Citations:    Fields:    Translation:Humans
    59. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 12; 27(12):1003.e1-1003.e13. PMID: 34537419; PMCID: PMC8504778.
      Citations:    Fields:    Translation:HumansCells
    60. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021 11; 27(11):913.e1-913.e12. PMID: 34329753.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    61. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806. PMID: 34264268; PMCID: PMC8341350.
      Citations: 8     Fields:    Translation:Humans
    62. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 01; 7(7):993-1003. PMID: 33956047; PMCID: PMC8283558.
      Citations: 2     Fields:    Translation:Humans
    63. Patel S, Girnius S, Bachegowda L, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Dhakal B, Fraser R, Davila O, Freytes CO, Chhabra S, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jul; 35(7):2141. PMID: 34091601.
      Citations:    Fields:    
    64. Patel S, Girnius S, Bachegowda L, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Dhakal B, Fraser R, Davila O, Freytes CO, Chhabra S, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jun; 35(6):1828. PMID: 33782538; PMCID: PMC8188513.
      Citations:    Fields:    
    65. Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res. 2021 07 01; 27(13):3744-3756. PMID: 33986022; PMCID: PMC8254785.
      Citations: 15     Fields:    Translation:HumansCells
    66. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407. PMID: 33942701.
      Citations:    Fields:    Translation:Humans
    67. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719. PMID: 33929874; PMCID: PMC10166368.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    68. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659. PMID: 33710337; PMCID: PMC7993097.
      Citations: 7     Fields:    Translation:Humans
    69. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, Blaise D, Herrera AF, Shouse G, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Carlo-Stella C, Casadei B, De Colella JMS, Spilleboudt C, Mohty M, Zinzani PL. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683. PMID: 33658659.
      Citations: 9     Fields:    Translation:Humans
    70. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5. PMID: 33965178.
      Citations:    Fields:    Translation:Humans
    71. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7. PMID: 33965187.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    72. Strati P, Cheng PTM, Steiner RE, Alcedo Andrade PE, Feng L, Sano D, Rao VA, Singh P, Miranda R, Gunther JR, Pinnix CC, Dabaja BS, Cuglievan B, Xing K, Villa D, Skinnider B, Sehn LH, Connors JM, Nieto Y, Ahmed S, Lee HJ, Savage KJ. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol. 2021 02; 192(3):560-567. PMID: 33517581.
      Citations:    Fields:    Translation:Humans
    73. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol. 2021 02; 192(4):e115-e120. PMID: 33486754.
      Citations: 1     Fields:    Translation:HumansCells
    74. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6. PMID: 33781521.
      Citations:    Fields:    Translation:Humans
    75. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther. 2021 03; 27(3):272.e1-272.e5. PMID: 33781539.
      Citations: 3     Fields:    Translation:Humans
    76. Saini N, Bashir Q, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH, Milton DR. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020 10 13; 4(19):4834-4837. PMID: 33027527; PMCID: PMC7556152.
      Citations: 1     Fields:    
    77. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789. PMID: 32492706; PMCID: PMC8209550.
      Citations: 3     Fields:    Translation:Humans
    78. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81. PMID: 32604096.
      Citations: 1     Fields:    Translation:Humans
    79. Kawedia JD, Handy VW, Shigle TL, Gulbis AM, Nieto Y, Andersson BS. Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biol Blood Marrow Transplant. 2020 09; 26(9):e232-e234. PMID: 32407883.
      Citations:    Fields:    Translation:Humans
    80. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020 08; 26(8):1439-1445. PMID: 32438043; PMCID: PMC7547798.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    81. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2020 05 01; 18(5):599-634. PMID: 32519831.
      Citations: 10     Fields:    Translation:Humans
    82. Patel S, Girnius S, Bachegowda L, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Dhakal B, Fraser R, Davila O, Freytes CO, Chhabra S, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 12; 34(12):3338-3347. PMID: 32313109; PMCID: PMC7572530.
      Citations: 7     Fields:    Translation:Humans
    83. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306. PMID: 32236526; PMCID: PMC7160275.
      Citations: 1     Fields:    Translation:Humans
    84. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865. PMID: 31961918; PMCID: PMC8212349.
      Citations: 8     Fields:    Translation:HumansCells
    85. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 02 06; 382(6):545-553. PMID: 32023374; PMCID: PMC7101242.
      Citations: 479     Fields:    Translation:HumansCellsCTClinical Trials
    86. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):e221-e238. PMID: 32037287; PMCID: PMC7190410.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    87. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, Qazilbash MH, Andersson BS. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Exp Hematol. 2020 01; 81:32-41. PMID: 31954171; PMCID: PMC7023992.
      Citations: 3     Fields:    Translation:HumansCells
    88. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126. PMID: 31917843; PMCID: PMC6960482.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    89. Badar T, Hari P, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A, D?vila O. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2020 01 01; 127(1):82-92. PMID: 32966625; PMCID: PMC7736245.
      Citations: 2     Fields:    Translation:Humans
    90. Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad II, Torres HA. Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. Clin Lymphoma Myeloma Leuk. 2020 03; 20(3):e124-e127. PMID: 31932250; PMCID: PMC8262650.
      Citations: 1     Fields:    Translation:HumansCells
    91. Varma A, Sui D, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH, Milton DR. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671. PMID: 31881283; PMCID: PMC8365505.
      Citations: 7     Fields:    Translation:HumansCells
    92. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083. PMID: 31786242.
      Citations: 1     Fields:    Translation:Humans
    93. Saini N, Ma J, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH, Milton DR. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787. PMID: 31481508.
      Citations: 2     Fields:    Translation:HumansCells
    94. Bashir Q, Chamoun K, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH, Milton DR. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma. 2019 12; 60(14):3536-3543. PMID: 31282244.
      Citations: 2     Fields:    Translation:Humans
    95. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235. PMID: 31243571.
      Citations:    Fields:    Translation:Humans
    96. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Fenske TS, Hamadani M, Bola?os-Meade J, Mussetti A, Sureda A. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2019 09; 25(9):1859-1868. PMID: 31132455; PMCID: PMC6755039.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    97. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. PMID: 30952672; PMCID: PMC6609955.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    98. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557. PMID: 30948491; PMCID: PMC6959196.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    99. Bashir Q, Thall PF, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH, Milton DR. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275. PMID: 30910541; PMCID: PMC9446704.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    100. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019 06; 25(6):1099-1106. PMID: 30794931; PMCID: PMC6559839.
      Citations: 1     Fields:    Translation:Humans
    101. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346. PMID: 30763728; PMCID: PMC8265611.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    102. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74. PMID: 30548467.
      Citations:    Fields:    Translation:HumansCells
    103. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 04; 25(4):683-688. PMID: 30579965; PMCID: PMC6453717.
      Citations: 3     Fields:    Translation:Humans
    104. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093. PMID: 30446740; PMCID: PMC8393277.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    105. Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018 Nov 02; 9(86):35611-35622. PMID: 30479692; PMCID: PMC6235025.
      Citations: 11     Fields:    
    106. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542. PMID: 30389035; PMCID: PMC6317874.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    107. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5. PMID: 30300461.
      Citations:    Fields:    Translation:Humans
    108. Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2019 03; 25(3):505-514. PMID: 30308325; PMCID: PMC8396110.
      Citations: 3     Fields:    Translation:Humans
    109. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61. PMID: 30360985; PMCID: PMC6371800.
      Citations: 2     Fields:    Translation:Humans
    110. Hu B, Thall P, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH, Milton DR. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452. PMID: 30032678.
      Citations: 8     Fields:    Translation:Humans
    111. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646. PMID: 30370365; PMCID: PMC6200878.
      Citations: 3     
    112. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. 2018 09; 103(9):e416-e418. PMID: 29622656; PMCID: PMC6119133.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    113. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):530-540. PMID: 29681481; PMCID: PMC7189963.
      Citations: 10     Fields:    Translation:Humans
    114. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609. PMID: 29501779; PMCID: PMC8212703.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    115. Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K, Oran B. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257. PMID: 29386198; PMCID: PMC6031309.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    116. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154. PMID: 29452771.
      Citations: 1     Fields:    Translation:Humans
    117. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant. 2018 03; 53(3):315-325. PMID: 29269797; PMCID: PMC8360209.
      Citations: 2     Fields:    Translation:Humans
    118. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2018 Jan 09; 9(3):3908-3921. PMID: 29423093; PMCID: PMC5790510.
      Citations: 23     Fields:    
    119. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018 04; 32(4):986-995. PMID: 29263438; PMCID: PMC5871538.
      Citations: 21     Fields:    Translation:Humans
    120. Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM, Im JS. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol. 2017 Nov; 41(11):1483-1490. PMID: 28834808; PMCID: PMC9994461.
      Citations: 1     Fields:    Translation:Humans
    121. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biol Blood Marrow Transplant. 2018 03; 24(3):478-485. PMID: 29079457; PMCID: PMC5826888.
      Citations: 14     Fields:    Translation:Humans
    122. Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50. PMID: 29277360; PMCID: PMC8224469.
      Citations: 5     Fields:    Translation:HumansCells
    123. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535. PMID: 28895206; PMCID: PMC8415170.
      Citations: 9     Fields:    Translation:Humans
    124. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017 Dec; 52(12):1616-1622. PMID: 28920949; PMCID: PMC5859934.
      Citations: 16     Fields:    Translation:Humans
    125. Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol. 2017 Sep; 13(9):901-923. PMID: 28766962; PMCID: PMC5584057.
      Citations: 24     Fields:    Translation:HumansAnimals
    126. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870. PMID: 28792260.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    127. Veltri LW, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q, Milton DR. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575. PMID: 28513828; PMCID: PMC5656242.
      Citations: 4     Fields:    Translation:Humans
    128. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292. PMID: 28522110; PMCID: PMC5844223.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    129. Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol. 2017 08; 178(4):561-570. PMID: 28485023; PMCID: PMC5672904.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    130. Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer. 2017 Aug 15; 123(16):3141-3149. PMID: 28472539; PMCID: PMC5544566.
      Citations: 21     Fields:    Translation:Humans
    131. Galvez-Silva J, Maher OM, Park M, Liu D, Hernandez F, Tewari P, Nieto Y. Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1276-1281. PMID: 28435146; PMCID: PMC8265610.
      Citations: 3     Fields:    Translation:Humans
    132. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma. 2017 11; 58(11):2705-2716. PMID: 28394191; PMCID: PMC5526721.
      Citations: 4     Fields:    Translation:HumansCells
    133. Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1059-1063. PMID: 28389254; PMCID: PMC8263315.
      Citations: 2     Fields:    Translation:Humans
    134. Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N. Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. J Cancer. 2017; 8(6):1009-1017. PMID: 28529613; PMCID: PMC5436253.
      Citations: 3     
    135. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466. PMID: 28295190; PMCID: PMC5856008.
      Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
    136. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion. 2017 04; 57(4):1052-1057. PMID: 28185276; PMCID: PMC8253453.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    137. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant. 2017 Apr; 52(4):580-587. PMID: 27991894; PMCID: PMC5382042.
      Citations: 20     Fields:    Translation:Humans
    138. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758. PMID: 27983760; PMCID: PMC5836501.
      Citations: 27     Fields:    Translation:Humans
    139. Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer. 2017 Apr 15; 123(8):1363-1371. PMID: 27984652; PMCID: PMC5811230.
      Citations: 4     Fields:    Translation:Humans
    140. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017 Mar; 98(3):263-268. PMID: 27862330; PMCID: PMC8318336.
      Citations: 2     Fields:    Translation:Humans
    141. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P, Freytes C. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb; 23(2):269-277. PMID: 27864161; PMCID: PMC5346183.
      Citations: 7     Fields:    Translation:Humans
    142. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292. PMID: 27816651; PMCID: PMC5926804.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    143. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenstr?m Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 01; 23(1):60-66. PMID: 27789362; PMCID: PMC5182098.
      Citations: 3     Fields:    Translation:Humans
    144. Mian I, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q, Milton DR. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837. PMID: 27680710; PMCID: PMC5138119.
      Citations: 10     Fields:    Translation:Humans
    145. Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 2016 Sep 27; 7(39):63829-63838. PMID: 27564097; PMCID: PMC5325407.
      Citations: 6     Fields:    Translation:HumansCells
    146. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ, Forget MA. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76. PMID: 27482888; PMCID: PMC5004935.
      Citations: 172     Fields:    Translation:HumansCellsCTClinical Trials
    147. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 10; 22(10):1893-1899. PMID: 27496215; PMCID: PMC5090978.
      Citations: 13     Fields:    Translation:Humans
    148. Milgrom SA, Nieto Y, Pinnix CC, Smith GL, Wogan CF, Rondon G, Medeiros LJ, Kebriaei P, Dabaja BS. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. J Med Case Rep. 2016 Jul 28; 10:209. PMID: 27465468; PMCID: PMC4964004.
      Citations: 1     Fields:    Translation:Humans
    149. Oliver NT, Nieto YL, Blechacz B, Anderlini P, Ariza-Heredia E, Torres HA. Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation. Bone Marrow Transplant. 2017 01; 52(1):138-140. PMID: 27427916.
      Citations: 4     Fields:    Translation:Humans
    150. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326. PMID: 27404668; PMCID: PMC5459484.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    151. Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma. 2017 02; 58(2):366-371. PMID: 27348707.
      Citations: 4     Fields:    Translation:Humans
    152. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312. PMID: 27247137; PMCID: PMC4946205.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    153. Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res. 2016 08; 47:100-8. PMID: 27294334; PMCID: PMC4961533.
      Citations: 2     Fields:    Translation:HumansCells
    154. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. PMID: 27203405; PMCID: PMC4992444.
      Citations: 18     Fields:    Translation:Humans
    155. Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN, Yabe M. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88. PMID: 26872013.
      Citations: 14     Fields:    Translation:HumansCells
    156. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016 07; 27(7):1317-23. PMID: 27091808; PMCID: PMC6357675.
      Citations: 10     Fields:    Translation:Humans
    157. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma. Biol Blood Marrow Transplant. 2016 07; 22(7):1333-1337. PMID: 27064056; PMCID: PMC5193224.
      Citations: 10     Fields:    Translation:Humans
    158. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785; PMCID: PMC5071733.
      Citations: 17     Fields:    Translation:HumansCells
    159. Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma. 2016 11; 57(11):2644-52. PMID: 26980288; PMCID: PMC8489015.
      Citations: 4     Fields:    Translation:HumansCells
    160. Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Exp Hematol. 2016 06; 44(6):458-65. PMID: 26976752; PMCID: PMC4864055.
      Citations: 3     Fields:    Translation:HumansCells
    161. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant. 2016 07; 51(7):999-1001. PMID: 26950376; PMCID: PMC8487077.
      Citations: 2     Fields:    Translation:HumansCells
    162. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5. PMID: 26921820; PMCID: PMC7176024.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    163. Shinozuka K, Tang H, Jones RB, Li D, Nieto Y. Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant. 2016 May; 22(5):843-9. PMID: 26743341; PMCID: PMC5703203.
      Citations: 3     Fields:    Translation:HumansCells
    164. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8. PMID: 26795083.
      Citations: 5     Fields:    Translation:Humans
    165. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Dec; 26(12):2507-8. PMID: 26487577; PMCID: PMC4855246.
      Citations: 1     Fields:    
    166. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant. 2016 Feb; 51(2):307-9. PMID: 26479980; PMCID: PMC9904336.
      Citations: 1     Fields:    Translation:Humans
    167. Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015 Oct 16; 5:e357. PMID: 26473529; PMCID: PMC4635192.
      Citations: 26     Fields:    Translation:HumansCells
    168. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015 Dec; 26(12):2490-5. PMID: 26416896; PMCID: PMC4855245.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    169. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol. 2015 Sep 25; 10:206. PMID: 26407853; PMCID: PMC4582821.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    170. Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Champlin RE, Shpall EJ, Oran B, Fern?ndez-Vi?a M. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70. PMID: 26250579; PMCID: PMC4591769.
      Citations: 13     Fields:    Translation:Humans
    171. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):687-93. PMID: 26361647; PMCID: PMC4644689.
      Citations: 14     Fields:    Translation:Humans
    172. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Oct; 26(10):2125-32. PMID: 26199392; PMCID: PMC5006186.
      Citations: 6     Fields:    Translation:Humans
    173. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. PMID: 26071868; PMCID: PMC4781754.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    174. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21. PMID: 25863759; PMCID: PMC4418191.
      Citations: 13     Fields:    Translation:Humans
    175. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82. PMID: 25863764; PMCID: PMC4418193.
      Citations: 43     Fields:    Translation:Humans
    176. Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U. Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1529-1531. PMID: 25937397; PMCID: PMC4830276.
      Citations: 4     Fields:    Translation:HumansCells
    177. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946. PMID: 25867648; PMCID: PMC4490031.
      Citations: 14     Fields:    Translation:Humans
    178. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6. PMID: 25963284; PMCID: PMC4516682.
      Citations: 3     Fields:    Translation:Humans
    179. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leuk Lymphoma. 2016 Feb; 57(2):445-447. PMID: 25804933; PMCID: PMC5215977.
      Citations: 3     Fields:    
    180. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92. PMID: 25778529; PMCID: PMC4424412.
      Citations: 50     Fields:    Translation:HumansCells
    181. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8. PMID: 25721897; PMCID: PMC4785590.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    182. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12. PMID: 25667989; PMCID: PMC4825327.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    183. Lee HC, Mulanovich V, Nieto Y. Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid leukemia. J Natl Compr Canc Netw. 2014 Dec; 12(12):1660-4; quiz 1664. PMID: 25505206.
      Citations: 1     Fields:    Translation:Humans
    184. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma. 2015 Feb; 56(2):533-5. PMID: 24882259.
      Citations: 2     Fields:    Translation:Humans
    185. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      Citations: 105     Fields:    Translation:Humans
    186. Hamdi A, Mulanovich VE, Matin SF, Landon G, Sircar K, Tu SM, Nieto Y. Isolated renal mucormycosis in a transplantation recipient. J Clin Oncol. 2015 Apr 01; 33(10):e50-1. PMID: 24821884.
      Citations: 2     Fields:    Translation:Humans
    187. Wang E, Gulbis A, Hart JW, Nieto Y. The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1382-9. PMID: 24816580.
      Citations: 3     Fields:    Translation:Humans
    188. Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J. 2014 Jan 10; 4:e171. PMID: 24413065; PMCID: PMC3913938.
      Citations: 8     Fields:    
    189. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5. PMID: 24169268; PMCID: PMC3913126.
      Citations: 8     Fields:    Translation:HumansCells
    190. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. 2013 Sep; 88(9):754-7. PMID: 23749720; PMCID: PMC3935820.
      Citations: 8     Fields:    Translation:Humans
    191. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8. PMID: 23872222; PMCID: PMC4157818.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    192. Nieto Y. Transplantation for refractory germ cell tumors: does it really make a difference? Curr Oncol Rep. 2013 Jun; 15(3):232-8. PMID: 23494829; PMCID: PMC8240097.
      Citations:    Fields:    Translation:Humans
    193. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013 Aug; 41(8):719-30. PMID: 23648290; PMCID: PMC3769691.
      Citations: 8     Fields:    Translation:HumansCells
    194. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1059-64. PMID: 23644077; PMCID: PMC8439154.
      Citations: 25     Fields:    Translation:Humans
    195. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013 Mar; 160(6):798-805. PMID: 23330820; PMCID: PMC4078723.
      Citations: 14     Fields:    Translation:Humans
    196. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15. PMID: 23234514; PMCID: PMC3805360.
      Citations: 184     Fields:    Translation:HumansCellsCTClinical Trials
    197. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7. PMID: 23128322; PMCID: PMC4077191.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    198. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013 May; 48(5):666-70. PMID: 23085830; PMCID: PMC10426811.
      Citations: 15     Fields:    Translation:Humans
    199. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer. 2012; 3:369-80. PMID: 23074378; PMCID: PMC3471078.
      Citations: 32     
    200. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44. PMID: 22796535; PMCID: PMC4320643.
      Citations: 88     Fields:    Translation:HumansCellsCTClinical Trials
    201. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1819-26. PMID: 22750645; PMCID: PMC4319530.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    202. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant. 2013 Jan; 48(1):26-31. PMID: 22732703; PMCID: PMC4346146.
      Citations: 4     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    203. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012 Oct; 40(10):800-10. PMID: 22687754; PMCID: PMC3447105.
      Citations: 21     Fields:    Translation:HumansCells
    204. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86. PMID: 22643322; PMCID: PMC4010147.
      Citations: 20     Fields:    Translation:Humans
    205. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1150-63. PMID: 22510384; PMCID: PMC3404151.
      Citations: 165     Fields:    Translation:Humans
    206. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012 Jun; 53(6):1239-41. PMID: 22132837; PMCID: PMC4493857.
      Citations: 4     Fields:    Translation:Humans
    207. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012 May; 53(5):901-6. PMID: 21988645; PMCID: PMC4225703.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    208. Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma. 2012 May; 53(5):973-81. PMID: 22023523; PMCID: PMC3867126.
      Citations: 11     Fields:    Translation:HumansCells
    209. Nieto Y, Shpall EJ. High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later? Biol Blood Marrow Transplant. 2012 Jan; 18(1):3-5. PMID: 22146617; PMCID: PMC8223587.
      Citations: 1     Fields:    Translation:Humans
    210. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar; 53(3):499-502. PMID: 21859247; PMCID: PMC4245073.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    211. Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9. PMID: 21646477.
      Citations: 9     Fields:    Translation:HumansCells
    212. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. 2012 Feb; 47(2):212-6. PMID: 21423123; PMCID: PMC4320641.
      Citations: 12     Fields:    Translation:Humans
    213. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1490-6. PMID: 21338705; PMCID: PMC4261630.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    214. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant. 2011 Mar; 17(3):412-20. PMID: 20674757; PMCID: PMC4031688.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    215. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8. PMID: 20054352; PMCID: PMC10405622.
      Citations:    Fields:    Translation:HumansCells
    216. Ramos CA, Saliba RM, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M, de P?dua Silva L. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):686-94. PMID: 20056165.
      Citations: 8     Fields:    Translation:Humans
    217. Vinh-Hung V, Nguyen NP, Truong P, Woodward W, Verkooijen HM, Promish D, Ueno NT, Tai P, Nieto Y, Joseph S, Janni W, Vicini F, Royce M, Storme G, Wallace AM, Vlastos G, Bouchardy C, Hortobagyi GN, Cserni G. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 2009 Dec; 5(10):1585-603. PMID: 20001797.
      Citations: 16     Fields:    Translation:Humans
    218. De la Cruz S, Santisteban M, Arbea L, Aristu J, Moreno M, Pina L, Sola J, Zornoza G, Nieto Y, Aramend?a JM, Espin?s J, Fern?ndez-Hidalgo O, Mart?nez-Monge R, Regueira FM. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. Cancer Chemother Pharmacol. 2010 Feb; 65(3):457-65. PMID: 19526361; PMCID: PMC8261625.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    219. Jones RB, Nieto Y, Wall D, Wingard JR, Rizzo JD, McCarthy PL, Oliansky D, Hahn T, ASBMT Steering Committee on Evidence-Based Reviews. Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy statement by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2009 Jun; 15(6):761-2. PMID: 19450763.
      Citations: 1     Fields:    Translation:Humans
    220. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S, K?rbling M. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23. PMID: 19450756; PMCID: PMC4352933.
      Citations: 39     Fields:    Translation:Humans
    221. Nieto Y, Shpall EJ. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol. 2009 Mar; 21(2):150-7. PMID: 19532017.
      Citations: 9     Fields:    Translation:Humans
    222. Ramos CA, Saliba RM, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M, de P?dua L. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009 Feb; 94(2):249-57. PMID: 19144658; PMCID: PMC2635398.
      Citations: 13     Fields:    Translation:HumansCells
    223. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7. PMID: 19041063; PMCID: PMC4112362.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    224. Viteri S, Redondo P, Nieto Y, Chopitea A, Ponz M, Gonz?lez-Cao M, D?az-Lagares A, Gonz?lez A, Espin?s J, Mart?n-Algarra S. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology. 2008; 74(1-2):12-6. PMID: 18536525.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    225. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2008 Feb; 14(2):137-80. PMID: 18215777.
      Citations: 17     Fields:    Translation:Humans
    226. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol. 2007 Oct 01; 25(28):4405-13. PMID: 17906204.
      Citations: 35     Fields:    Translation:HumansCells
    227. Nieto Y, Aldaz A, Zafra A, Zufia L, Viteri S, Aristu J, Centeno C, Moreno M, Sayar O, Rif?n J, P?rez-Calvo J, Vi?dez A, Aramend?a JM, Hern?ndez M. Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1324-37. PMID: 17950919.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    228. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007 Aug 06; 97(3):391-7. PMID: 17609662; PMCID: PMC2360317.
      Citations: 24     Fields:    Translation:Humans
    229. Nieto Y, De la Cruz S, Aristu J, Zubieta JL, Santisteban M, Fern?ndez Hidalgo O. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clin Transl Oncol. 2007 Jul; 9(7):465-7. PMID: 17652061.
      Citations: 5     Fields:    Translation:Humans
    230. Viteri S, Nieto Y, Aristu J, Ponz M, Gonz?lez Cao M, Garr?n C, Mart?n Algarra S. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab. Clin Transl Oncol. 2007 Feb; 9(2):119-20. PMID: 17329225.
      Citations: 1     Fields:    Translation:Humans
    231. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2910-6. PMID: 16782931.
      Citations: 63     Fields:    Translation:Humans
    232. Nieto Y, Espin?s J, Rif?n J, P?rez-Calvo J. Idiopathic hyperammonemia following high-dose chemotherapy. Bone Marrow Transplant. 2006 May; 37(9):899. PMID: 16547487.
      Citations: 6     Fields:    Translation:Humans
    233. Nieto Y, Santisteban M, Aramend?a JM, Fern?ndez-Hidalgo O, Garc?a-Manero M, L?pez G. Docetaxel administered during pregnancy for inflammatory breast carcinoma. Clin Breast Cancer. 2006 Feb; 6(6):533-4. PMID: 16595038.
      Citations: 10     Fields:    Translation:Humans
    234. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, McSweeney PA, Bar?n A. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant. 2006 Feb; 12(2):217-25. PMID: 16443519.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    235. Jones R, Nieto Y, Rizzo JD, Wall D, Wingard JR, McCarthy P, Hahn T, Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplan. The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2005 Nov; 11(11):819-22. PMID: 16275587.
      Citations: 1     Fields:    Translation:Humans
    236. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, Zeng C, Baron A, McSweeney PA. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant. 2005 Sep; 36(5):443-51. PMID: 15995712.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    237. Rosinski SL, McNiece IK, Shpall EJ, Clough N, Russell P, Blunk B, Nieto Y. Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplant. 2005 Sep; 36(5):425-30. PMID: 15980880.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    238. Nieto Y, Shpall EJ, Bearman SI, Jones RB. Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. Am J Clin Oncol. 2005 Jun; 28(3):248-54. PMID: 15923796.
      Citations:    Fields:    Translation:Humans
    239. Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Jones RB, Bar?n AE. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biol Blood Marrow Transplant. 2005 Apr; 11(4):297-306. PMID: 15812395.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    240. Nieto Y. DNA-binding agents. Cancer Chemother Biol Response Modif. 2005; 22:163-203. PMID: 16110612.
      Citations: 1     Fields:    Translation:HumansAnimals
    241. Robertson KB, Barron MA, Nieto Y. West Nile virus infection in bone marrow transplant patients. Bone Marrow Transplant. 2004 Nov; 34(9):823-4. PMID: 15361905.
      Citations: 3     Fields:    Translation:Humans
    242. Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Chao N, Rizzieri D, Gasparetto C, Matthes S, Jones RB, Bar?n AE. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res. 2004 Nov 01; 10(21):7136-43. PMID: 15534084.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    243. Nieto Y, Jones RB, Shpall EJ. Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol. 2004 Nov; 26(1-2):31-56. PMID: 15368078.
      Citations: 6     Fields:    Translation:Humans
    244. Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-Vasquez V, McSweeney PA, Bearman SI, Murphy J, Jones RB. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res. 2004 Aug 01; 10(15):5076-86. PMID: 15297410.
      Citations: 14     Fields:    Translation:HumansCells
    245. Parikh CR, Sandmaier BM, Storb RF, Blume KG, Sahebi F, Maloney DG, Maris MB, Nieto Y, Edelstein CL, Schrier RW, McSweeney P. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol. 2004 Jul; 15(7):1868-76. PMID: 15213275.
      Citations: 12     Fields:    Translation:HumansCells
    246. Nieto Y, Franklin WA, Jones RB, Berman SI, Pellom J, Shpall EJ, Bar?n AE. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant. 2004 Jun; 10(6):415-25. PMID: 15148495.
      Citations: 6     Fields:    Translation:HumansCells
    247. Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res. 2004 Apr 15; 10(8):2609-17. PMID: 15102662.
      Citations: 8     Fields:    Translation:Humans
    248. Jones RB, Stockerl-Goldstein KE, Klein J, Murphy J, Blume KG, Dansey R, Martinez C, Matthes S, Nieto Y. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. Biol Blood Marrow Transplant. 2004 Apr; 10(4):276-82. PMID: 15077226.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    249. Nieto Y, Jones RB, Shpall EJ. High-dose chemotherapy for breast cancer: is another look warranted? Curr Opin Oncol. 2004 Mar; 16(2):114-9. PMID: 15075901.
      Citations:    Fields:    Translation:Humans
    250. Nieto Y, Vaughan WP. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant. 2004 Feb; 33(3):259-69. PMID: 14647243.
      Citations: 14     Fields:    Translation:Humans
    251. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 2003 Dec; 17(12):2538-40. PMID: 14523458.
      Citations: 1     Fields:    Translation:Humans
    252. Medeiros BC, Kolhouse JF, Cagnoni PJ, Ryder J, Nieto Y, Rabinovitch R, Shpall EJ, Bearman SI, Jones RB, McSweeney PA. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. Bone Marrow Transplant. 2003 Jun; 31(11):1053-5. PMID: 12774059.
      Citations: 1     Fields:    Translation:Humans
    253. Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica. 2003 Feb; 88(2):201-11. PMID: 12604410.
      Citations: 7     Fields:    Translation:Humans
    254. Nieto Y. DNA-binding agents. Cancer Chemother Biol Response Modif. 2003; 21:171-209. PMID: 15338745.
      Citations:    Fields:    Translation:Humans
    255. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Razook C, Matthes S, Bearman SI, Bar?n A. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):707-18. PMID: 11821452.
      Citations: 19     Fields:    Translation:Humans
    256. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002; 8(7):368-76. PMID: 12171483.
      Citations: 91     Fields:    Translation:HumansCellsCTClinical Trials
    257. Nieto Y, Jones RB. DNA-binding agents. Cancer Chemother Biol Response Modif. 2002; 20:197-225. PMID: 12703206.
      Citations: 1     Fields:    Translation:HumansAnimals
    258. Nieto Y, Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Rabinovitch RA, McSweeney PA. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. Bone Marrow Transplant. 2001 Dec; 28(11):1083-6. PMID: 11781620.
      Citations:    Fields:    Translation:Humans
    259. Nieto Y. Pharmacodynamics of high-dose chemotherapy. Curr Drug Metab. 2001 Mar; 2(1):53-66. PMID: 11465151.
      Citations: 1     Fields:    Translation:HumansAnimals
    260. Nieto Y, Jones RB. DNA-binding agents. Cancer Chemother Biol Response Modif. 2001; 19:189-213. PMID: 11686014.
      Citations:    Fields:    Translation:HumansCells
    261. McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermitt J, Hogan C, Murphy J, Shpall EJ. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood. 2000 Nov 01; 96(9):3001-7. PMID: 11049977.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    262. Nieto Y, Russ P, Everson G, Bearman SI, Cagnoni PJ, Jones RB, Shpall EJ. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2000 Jul; 26(1):109-11. PMID: 10918414.
      Citations: 14     Fields:    Translation:Humans
    263. Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 2000 May; 18(10):2070-80. PMID: 10811672.
      Citations: 5     Fields:    Translation:Humans
    264. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95. PMID: 11063377.
      Citations: 3     Fields:    Translation:Humans
    265. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant. 2000; 6(2A):198-203. PMID: 10816028.
      Citations: 11     Fields:    Translation:Humans
    266. Nieto Y, Shpall EJ. High-dose chemotherapy for breast cancer. Cancer Treat Res. 2000; 103:77-114. PMID: 10948443.
      Citations:    Fields:    Translation:HumansCells
    267. Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res. 1999 Nov; 5(11):3425-31. PMID: 10589754.
      Citations: 6     Fields:    Translation:Humans
    268. Nieto Y, Shpall EJ. Autologous stem-cell transplantation for solid tumors in adults. Hematol Oncol Clin North Am. 1999 Oct; 13(5):939-68, vi. PMID: 10553256.
      Citations: 1     Fields:    Translation:Humans
    269. Bearman S, Vredenburgh J, Cagnoni P, Shpall E, Nieto Y, Ross M, Peters W, Jones R. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. Bone Marrow Transplant. 1999 Sep; 24(5):491-5. PMID: 10482932.
      Citations:    Fields:    Translation:Humans
    270. Nieto Y, Cagnoni PJ, Shpall EJ, Matthes S, Jones RB, Bearman SI, Bar?n A. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res. 1999 Jul; 5(7):1731-7. PMID: 10430076.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    271. Nieto Y, Ross M, Gianani R, Shpall EJ, Cagnoni PJ, Bearman SI, Jones RB. Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. Bone Marrow Transplant. 1999 Jun; 23(12):1323-4. PMID: 10414924.
      Citations: 3     Fields:    Translation:Humans
    272. Nieto Y, Xu X, Cagnoni PJ, Matthes S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. Clin Cancer Res. 1999 Apr; 5(4):747-51. PMID: 10213208.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    273. McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ. Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematol Cell Ther. 1999 Apr; 41(2):82-6. PMID: 10344558.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    274. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Jones RB, Bar?n A. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res. 1999 Mar; 5(3):501-6. PMID: 10100699.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    275. Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK. Peripheral blood stem cell transplantation in breast cancer. Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun; 12(1-2):219-32. PMID: 11000995.
      Citations: 2     Fields:    Translation:Humans
    276. Nieto Y, Alonso JL, Ayala F, Ortega L, Casado A, Mart?n M, D?az-Rubio E. End-stage acute hepatic failure as clinical presentation of liver metastases from breast cancer. Tumori. 1998 Sep-Oct; 84(5):616-7. PMID: 9862530.
      Citations: 3     Fields:    Translation:Humans
    277. Rubio MA, Redondo MJ, Cabrerizo L, Romeo S, Alonso JL, Nieto YL, Ayala F, Ballesteros MD, Mart?n M. [Parenteral nutrition of patients under intensive chemotherapy: comparative study of two lipid emulsions]. Nutr Hosp. 1998 Jul-Aug; 13(4):177-80. PMID: 9780749.
      Citations:    Fields:    Translation:Humans
    278. Nieto Y, Alonso JL, Casado A, Ayala F, Mart?n M, L?pez-Mart?n JA, Rodr?guez-Lescure A, D?az-Rubio E. Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. Breast Cancer Res Treat. 1998 Jul; 50(2):167-74. PMID: 9822221.
      Citations:    Fields:    Translation:Humans
    279. Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Ross M, Matthes S, Dunbar SE, Jones RB, Bar?n AE. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998 May; 16(5):1661-8. PMID: 9586876.
      Citations: 6     Fields:    Translation:Humans
    280. Nieto Y, Cagnoni PJ, Jones RB. Standard versus high-dose therapy in 10+ breast cancer. J Clin Oncol. 1998 Feb; 16(2):810-1. PMID: 9469383.
      Citations:    Fields:    Translation:Humans
    281. Nieto Y, Cagnoni PJ, Shpall EJ. High-dose chemotherapy in gynecologic malignancies. Cancer Treat Res. 1998; 95:277-85. PMID: 9619289.
      Citations:    Fields:    Translation:Humans
    282. Casado A, Llorente L, Nieto Y, Ayala F, Alonso JL, Villegas A, Mart?n M, L?pez Mart?n JA, Rodr?guez Lescure A, P?rez Calvo J, P?rez L?pez C, D?az-Rubio E. [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. Med Clin (Barc). 1997 Dec 06; 109(20):775-81. PMID: 9493155.
      Citations:    Fields:    Translation:Humans
    283. Martin M, Casado A, Rodriguez-Lescure A, Nieto Y, Ayala F, Diaz-Rubio E, L?pez-Martin JA. Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. Oncology (Williston Park). 1997 Sep; 11(9 Suppl 10):83-5. PMID: 9348575.
      Citations: 1     Fields:    Translation:Humans
    284. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB. Peripheral blood stem cell harvesting and CD34-positive cell selection. Cancer Treat Res. 1997; 77:143-57. PMID: 9071502.
      Citations: 1     Fields:    Translation:HumansCells
    285. Alonso JL, Nieto Y, L?pez JA, Mart?n M, D?az-Rubio E. Ifosfamide encephalopathy and methylene-blue: a case report. Ann Oncol. 1996 Aug; 7(6):643-4. PMID: 8879383.
      Citations: 4     Fields:    Translation:Humans
    286. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leukemia and Lymphoma. 1-6.
    287. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer Journal. 4.
    288. Hematopoietic Cell Transplantation for Breast Cancer. 931-947.
    289. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma. Leukemia and Lymphoma.
    290. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation. 23:269-277.
    291. The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies. Seminars in Breast Disease. 3:144-152.
    292. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer.
    293. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation. 22:961-965.
    294. Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30<sup>+</sup> Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biology of Blood and Marrow Transplantation. 21:1529-1531.
    295. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas. Experimental Hematology.
    296. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Annals of Oncology. 26:2125-2132.
    297. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplantation.
    298. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation. Journal of Medical Case Reports. 10.
    299. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    300. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation.
    301. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia. 15:472-476.
    302. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leukemia Research. 47:100-108.
    303. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clinical Lymphoma, Myeloma and Leukemia. 15:687-693.
    304. Phase i trials using sleeping beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation. 126:3363-3376.
    305. Intratumoral heterogeneity. Cancer.
    306. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    307. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leukemia and Lymphoma. 56:533-535.
    308. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    309. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 23:285-292.
    310. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biology of Blood and Marrow Transplantation. 23:60-66.
    311. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 122:3316-3326.
    312. Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation. Bone Marrow Transplantation.
    313. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 16:122-128.
    314. Autologous Hematopoietic Cell Transplantation for Breast Cancer and Germ-cell Tumors. 739-750.
    315. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 100:1361-1370.
    316. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplantation.
    317. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation. 50:939-946.
    318. Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies. Biology of Blood and Marrow Transplantation.
    319. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leukemia and Lymphoma. 1-9.
    320. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiation Oncology. 10.
    321. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 128:297-312.
    322. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 7:63829-63838.
    323. Long-term follow-up of patients with breast cancer transplanted with autologous ex vivo expanded peripheral blood progenitor cells. Cell Preservation Technology. 4:4-8.
    324. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doi. Annals of Oncology. 26:2507-2508.
    325. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma. Annals of Oncology. 26:2490-2495.
    326. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation.
    327. Biology of Blood and Marrow Transplantation. 22:1893-1899.
    NIETO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (612)
    Explore
    _
    Co-Authors (130)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _